- Donesta® Phase II study on track to yield top line data late Q1 2018
- 260 women recruited in total, of which over 200 have completed at least 12 weeks of treatment as part of the Phase II study
- 12-week data generated for an additional 15% of study subjects in order to improve robustness of analysis
Liège, Belgium, 25 January 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the last subject completed the E4 Relief Phase II study of Donesta®, Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4) for Vasomotor Menopausal Symptoms (VMS) relief. Top-line data remain on track to be available late in the first quarter of 2018.